Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Pepsi’s move into a healthier beverages market was a way to win back customers. After all, according to a study by Harvard ...